Several other equities analysts also recently issued reports on EVH. FBR & Co upped their price objective on shares of Evolent Health from $16.00 to $24.00 and gave the company an outperform rating in a report on Wednesday, July 13th. Canaccord Genuity reiterated a buy rating and issued a $30.00 target price on shares of Evolent Health in a research report on Wednesday, July 13th. Leerink Swann reiterated an outperform rating and issued a $20.00 target price on shares of Evolent Health in a research report on Sunday, July 17th. Finally, Jefferies Group began coverage on Evolent Health in a research report on Tuesday, July 26th. They issued a buy rating and a $28.00 target price on the stock. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The company has an average rating of Buy and an average target price of $22.50.
Shares of Evolent Health (NYSE:EVH) opened at 25.15 on Friday. Evolent Health has a 52-week low of $8.14 and a 52-week high of $26.84. The stock’s 50 day moving average is $23.76 and its 200 day moving average is $18.22. The company’s market cap is $1.51 billion.
Evolent Health (NYSE:EVH) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.04. Evolent Health had a negative net margin of 76.55% and a negative return on equity of 5.04%. The firm had revenue of $56.50 million for the quarter, compared to the consensus estimate of $51.96 million. During the same quarter in the prior year, the company posted ($0.95) earnings per share. The company’s revenue for the quarter was up 443.3% compared to the same quarter last year. Equities analysts forecast that Evolent Health will post ($0.54) EPS for the current year.
In related news, President Seth Blackley sold 167,672 shares of the company’s stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $21.54, for a total value of $3,611,654.88. Following the sale, the president now owns 869,848 shares in the company, valued at $18,736,525.92. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Board Co Advisory sold 1,936,529 shares of the company’s stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $22.50, for a total value of $43,571,902.50. Following the completion of the sale, the insider now owns 4,445,879 shares in the company, valued at approximately $100,032,277.50. The disclosure for this sale can be found here. 8.85% of the stock is owned by corporate insiders.
Large investors have recently modified their holdings of the stock. EAM Investors LLC purchased a new stake in shares of Evolent Health during the second quarter worth approximately $3,971,000. Emerald Acquisition Ltd. bought a new stake in Evolent Health during the second quarter valued at approximately $1,301,000. Swiss National Bank raised its stake in Evolent Health by 90.2% in the second quarter. Swiss National Bank now owns 32,900 shares of the company’s stock valued at $632,000 after buying an additional 15,600 shares in the last quarter. California State Teachers Retirement System raised its stake in Evolent Health by 14.0% in the second quarter. California State Teachers Retirement System now owns 31,915 shares of the company’s stock valued at $613,000 after buying an additional 3,912 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in Evolent Health by 14.2% in the second quarter. Bank of New York Mellon Corp now owns 341,806 shares of the company’s stock valued at $6,563,000 after buying an additional 42,414 shares in the last quarter. Hedge funds and other institutional investors own 40.22% of the company’s stock.
Evolent Health Company Profile
Evolent Health, Inc supports integrated health systems in their migration towards value-based care and population health management. The Company’s services include providing customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services and health plan administration services.
Receive News & Ratings for Evolent Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.